Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
More Stories
Boeing delivered 30 airplanes in December, but gap with Airbus widened in 2024
Boeing delivered 348 airplanes in 2024, less than half of rival Airbus's deliveries.
CFPB sues Capital One for ‘cheating’ customers out of over $2 billion in interest
The Consumer Financial Protection Bureau announced it was suing Capital One for "cheating" customers out of more than $2 billion...
Southwest Airlines pauses corporate hiring, most summer internships to cut costs
Southwest had been under pressure from activist Elliott Investment Management to increase returns.
JPMorgan Chase exec Daniel Pinto, longtime No. 2 to Jamie Dimon, will step down in June
Pinto has worked at JPMorgan and a predecessor firm for more than four decades.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes...
Netflix and Comcast among companies donating to LA wildfire relief effort
Companies are pledging millions in donations to aid in relief efforts for the Los Angeles wildfires.